{"id":"NCT00632736","sponsor":"GlaxoSmithKline","briefTitle":"An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease","officialTitle":"An Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 101468/168 and 101468/169","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-02","primaryCompletion":"2010-03","completion":"2010-03","firstPosted":"2008-03-11","resultsPosted":"2010-12-24","lastUpdate":"2017-03-23"},"enrollment":419,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson Disease","Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"Ropinirole XL (formerly CR)","otherNames":[]}],"arms":[{"label":"Ropinirole XL (formerly CR)","type":"ACTIVE_COMPARATOR"}],"summary":"To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease","primaryOutcome":{"measure":"Number of Participants With the Indicated Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"13 February 2004 through 31 March 2010","effectByArm":[{"arm":"Ropinirole XL","deltaMin":365,"sd":null}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":75,"countries":["United States","Belgium","Czechia","France","Hungary","Italy","Poland","Spain","United Kingdom"]},"refs":{"pmids":["25495896"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":109,"n":419},"commonTop":["Back pain","Hallucination","Oedema peripheral","Somnolence","Dyskinesia"]}}